Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02466009 · ClinicalTrials.gov registry record · Phase 2
Regorafenib in Metastatic Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Cancer, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT02466009 is a Phase 2 study of Metastatic Colorectal Cancer that has completed, run by University of Rochester. The registered enrollment target is 27 participants, below the 185-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02466009, a Phase 2 study of Metastatic Colorectal Cancer, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the study is to measure high grade (3-5) toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer.
Conditions Studied
Interventions
- DRUG Regorafenib
Study Locations (4)
Minnesota
- Mayo Clinic - Rochester
New York
- University of Rochester - Rochester
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-03 |
| Est. Completion | 2022-03-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02466009
The ClinicalTrials.gov registry entry for NCT02466009 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (85% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Regorafenib is the first listed.
NCT02466009 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Minnesota, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02466009 about?
NCT02466009 is a clinical study titled "Regorafenib in Metastatic Colorectal Cancer". The purpose of the study is to measure high grade (3-5) toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer.
What is the current status of trial NCT02466009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2015-03. Estimated completion is 2022-03-09.
What conditions does trial NCT02466009 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT02466009?
The interventions under investigation include: Regorafenib (DRUG).
Who is sponsoring clinical trial NCT02466009?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02466009 being conducted?
This trial has 4 study locations across Minnesota, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
-
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.